Ebook: The Immune Synapse as a Novel Target for Therapy

The immune synapse can be compared to a molecular machine that controls T cell activation when getting in contact with an antigen-presenting cell (APC). The immune synapse is involved in the transfer of information across the T cell–APC junction. It plays an essential role in the control and nature of the immune response.

In recent years several approaches have been developed to reprogram the immune response by targeting molecules involved in the immune synapse. Monoclonal antibodies, such as those targeting the lymphocyte co-receptor, costimulatory and adhesion molecules (CD3, CD4, CD40L, CTLA4-Ig, LFA-1), or altered peptide ligands have been shown capable of inducing immune tolerance in transplantation, autoimmunity and allergy.

This volume discusses the progress in the field, from basic science to clinical trials, and the major mechanisms involved. It is of interest to clinicians and researchers working in this area.

---

The immune synapse can be compared to a molecular machine that controls T cell activation when getting in contact with an antigen-presenting cell (APC). The immune synapse is involved in the transfer of information across the T cell–APC junction. It plays an essential role in the control and nature of the immune response.

In recent years several approaches have been developed to reprogram the immune response by targeting molecules involved in the immune synapse. Monoclonal antibodies, such as those targeting the lymphocyte co-receptor, costimulatory and adhesion molecules (CD3, CD4, CD40L, CTLA4-Ig, LFA-1), or altered peptide ligands have been shown capable of inducing immune tolerance in transplantation, autoimmunity and allergy.

This volume discusses the progress in the field, from basic science to clinical trials, and the major mechanisms involved. It is of interest to clinicians and researchers working in this area.

---

The immune synapse can be compared to a molecular machine that controls T cell activation when getting in contact with an antigen-presenting cell (APC). The immune synapse is involved in the transfer of information across the T cell–APC junction. It plays an essential role in the control and nature of the immune response.

In recent years several approaches have been developed to reprogram the immune response by targeting molecules involved in the immune synapse. Monoclonal antibodies, such as those targeting the lymphocyte co-receptor, costimulatory and adhesion molecules (CD3, CD4, CD40L, CTLA4-Ig, LFA-1), or altered peptide ligands have been shown capable of inducing immune tolerance in transplantation, autoimmunity and allergy.

This volume discusses the progress in the field, from basic science to clinical trials, and the major mechanisms involved. It is of interest to clinicians and researchers working in this area.

Content:
Front Matter....Pages i-xii
The immune synapse and T cell activation: regulation by chemokines....Pages 1-13
The induction of regulatory T cells by targeting the immune synapse....Pages 15-34
Infiltrating the immunological synapse: prospects for the use of altered peptide ligands for the treatment of immune pathology....Pages 35-47
Targeting CD4 for the induction of dominant tolerance....Pages 49-56
Anti-CD3: from T cell depletion to tolerance induction....Pages 57-70
Immune modulation by CD40L blockade....Pages 71-86
CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance....Pages 87-106
Adhesion molecules as therapeutic targets....Pages 107-128
E3 ubiquitin ligases and immune tolerance: Targeting the immune synapse from within?....Pages 129-146
FOXP3 biochemistry will lead to novel drug approaches for vaccines and diseases that lack suppressor T cells....Pages 147-154
Transforming growth factor-?: From its effect in T cell activation to a role in dominant tolerance....Pages 155-168
From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic....Pages 169-185
Back Matter....Pages 187-192

---

The immune synapse can be compared to a molecular machine that controls T cell activation when getting in contact with an antigen-presenting cell (APC). The immune synapse is involved in the transfer of information across the T cell–APC junction. It plays an essential role in the control and nature of the immune response.

In recent years several approaches have been developed to reprogram the immune response by targeting molecules involved in the immune synapse. Monoclonal antibodies, such as those targeting the lymphocyte co-receptor, costimulatory and adhesion molecules (CD3, CD4, CD40L, CTLA4-Ig, LFA-1), or altered peptide ligands have been shown capable of inducing immune tolerance in transplantation, autoimmunity and allergy.

This volume discusses the progress in the field, from basic science to clinical trials, and the major mechanisms involved. It is of interest to clinicians and researchers working in this area.

Content:
Front Matter....Pages i-xii
The immune synapse and T cell activation: regulation by chemokines....Pages 1-13
The induction of regulatory T cells by targeting the immune synapse....Pages 15-34
Infiltrating the immunological synapse: prospects for the use of altered peptide ligands for the treatment of immune pathology....Pages 35-47
Targeting CD4 for the induction of dominant tolerance....Pages 49-56
Anti-CD3: from T cell depletion to tolerance induction....Pages 57-70
Immune modulation by CD40L blockade....Pages 71-86
CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance....Pages 87-106
Adhesion molecules as therapeutic targets....Pages 107-128
E3 ubiquitin ligases and immune tolerance: Targeting the immune synapse from within?....Pages 129-146
FOXP3 biochemistry will lead to novel drug approaches for vaccines and diseases that lack suppressor T cells....Pages 147-154
Transforming growth factor-?: From its effect in T cell activation to a role in dominant tolerance....Pages 155-168
From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic....Pages 169-185
Back Matter....Pages 187-192
....